C4 Therapeutics, Inc. Contract with Customer, Liability, Noncurrent
C4 Therapeutics, Inc. (CCCC) had Contract with Customer, Liability, Noncurrent of $13.71 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2026-08-11
- 2026-06-30: Contract with Customer, Liability, Noncurrent $13.71M.
- 2026-03-31: Contract with Customer, Liability, Noncurrent $15.44M.
- 2025-12-31: Contract with Customer, Liability, Noncurrent $15.84M.
- 2025-09-30: Contract with Customer, Liability, Noncurrent $19.89M.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $13.71M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $15.44M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $15.84M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $19.89M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $21.15M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $25.12M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $28.46M 10-K · filed 2026-02-26 |
| 2024-09-30 | $28.65M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $16.91M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $20.71M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $21.81M 10-K · filed 2025-02-27 |
| 2023-09-30 | $19.62M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $24.65M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $15.85M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $16.89M 10-K · filed 2024-02-22 |
| 2022-09-30 | $16.77M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $17.99M 10-Q · filed 2022-08-04 |
| 2021-12-31 | $24.37M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |